STOCK TITAN

Pasithea Therapeutics Corp - KTTA STOCK NEWS

Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.

Pasithea Therapeutics Corp (NASDAQ: KTTA) is a clinical-stage biotechnology company advancing novel therapies for central nervous system disorders and genetic conditions. This dedicated news hub provides investors and industry observers with timely updates on the company's scientific progress, regulatory milestones, and strategic initiatives.

Our curated collection offers comprehensive tracking of KTTA's developments including clinical trial updates for its lead candidate PAS-004, research collaborations, and advancements in treating conditions like Neurofibromatosis Type 1 and ALS. The content is organized to help stakeholders efficiently monitor the company's progress in neuroscience innovation and drug development.

Key updates cover regulatory filings, partnership announcements, peer-reviewed research publications, and clinical trial results. All content maintains strict editorial standards to ensure accuracy and relevance for both professional investors and those new to biotech equities.

Bookmark this page for centralized access to verified information about Pasithea's therapeutic pipeline, including its work on MEK inhibitors and translational medicine approaches. Check back regularly for essential updates that could impact long-term research trajectories and market positioning.

Rhea-AI Summary
Pasithea Therapeutics Corp. has completed manufacturing of GMP-compliant Phase 1 clinical supplies of its lead product candidate PAS-004, a next-generation macrocyclic MEK Inhibitor. The company expects to file an IND application with the FDA in the second half of 2023 and plans to initiate a Phase 1 clinical trial by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. has received an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock. The proposal includes $0.60 in cash plus $0.25 worth of Lucy common stock per share. Pasithea's Board of Directors will review and evaluate the proposal to determine the best course of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Pasithea Therapeutics Corp. to participate in EF Hutton Global Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
conferences
-
Rhea-AI Summary

Pasithea Therapeutics Corp. (KTTA) announced that Prof. Lawrence Steinman will deliver a keynote address at the AAAS Annual Meeting on March 4, 2023. Prof. Steinman's research linking the Epstein-Barr virus to multiple sclerosis (MS) was recognized as a runner-up for the 2022 Science Magazine Breakthrough of the Year.

The company's PAS-002 program aims to develop a DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS, providing potential treatment avenues for this chronic autoimmune disease affecting 2.8 million worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
none
-
Rhea-AI Summary

Pasithea Therapeutics Corp. announced that Lawrence Steinman, Chairman, will deliver a significant lecture at the ACTRIMS Forum in San Diego on February 23, 2023. The event, themed “MS: Going Viral,” focuses on the role of the Epstein-Barr virus in Multiple Sclerosis (MS), which relates to the Company's PAS-002 drug discovery program. PAS-002 aims to create an engineered DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS. MS affects 2.8 million people globally, with relapsing remitting MS being the most common type. Steinman's research was recognized as a runner-up for Science Magazine’s 2022 Breakthrough of the Year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.66%
Tags
none
Rhea-AI Summary

Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its Chairman, Prof. Lawrence Steinman, will receive the 2023 Pioneer in Medicine Award for significant contributions to brain mapping and therapeutics at the 20th Annual Gathering for the Cure on February 17, 2023. This award is presented by the Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping Foundation, recognizing pioneering work in fields like multiple sclerosis (MS). The company is focusing on developing a proprietary engineered DNA plasmid vaccine, PAS-002, targeting GlialCAM for MS treatment, affecting over 2.3 million people worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
none
-
Rhea-AI Summary

Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced a partnership with WuXi STA to manufacture the active pharmaceutical ingredient for its MEK Inhibitor PAS-004, targeting Neurofibromatosis Type 1 (NF1). This collaboration is pivotal as the company aims to submit its Investigational New Drug (IND) application to the FDA in the second half of 2023, following successful pre-clinical testing. PAS-004 has received orphan drug designation and is expected to commence a Phase 1 clinical trial soon. WuXi STA is recognized for meeting rigorous global quality standards, reinforcing the development of PAS-004 into a promising therapeutic option for CNS disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced the results of its Special Meeting of Stockholders held on December 9, 2022. Approximately 67% of stockholders voted against proposals to remove the current Board of Directors, representing about 12.7 million shares or 44% of total shares. This decision allows the current Board to continue overseeing the company's strategy. CEO Dr. Tiago Reis Marques expressed gratitude for stockholder support and commitment to developing innovative treatments for CNS disorders, including ALS and Multiple Sclerosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
none
Rhea-AI Summary

Pasithea Therapeutics Corp. (Nasdaq: KTTA) has reached a Settlement and Cooperation Agreement with the Camac Group, resolving all litigation issues. The Camac Group will observe a three-year standstill and has agreed to sell 3,205,282 shares of common stock at $1.0003 each, reflecting the five-day average price. Pasithea will also reimburse certain expenses. CEO Tiago Reis Marques expressed optimism about this agreement, stating it allows the company to focus on advancing its CNS therapies. The Board of Directors will continue overseeing the company's strategy following a recent Special Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
none
Pasithea Therapeutics Corp

Nasdaq:KTTA

KTTA Rankings

KTTA Stock Data

3.73M
2.46M
19.08%
6.09%
0.69%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI BEACH